The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028.
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Sarina Anne Piha-Paul
Research Funding - Biomarin; GlaxoSmithKline; Helix BioPharma; Merck; Novartis; Puma Biotechnology
 
Shadia Ibrahim Jalal
No Relationships to Disclose
 
Hieu Mai-Dang
Employment - Merck
Stock and Other Ownership Interests - Johnson & Johnson (I)
 
Sammy Yuan
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Minori Koshiji
Employment - Merck
Stock and Other Ownership Interests - Lilly
 
Ildiko Csiki
Employment - GlaxoSmithKline; Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
Research Funding - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - GlaxoSmithKline; Merck
 
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche